Online inquiry

IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6048MR)

This product GTTS-WQ6048MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Giant cell arteritis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6048MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11226MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ13837MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ9741MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ10344MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ15960MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ7330MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ9640MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ1025MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW